Paras Biopharmaceuticals Finland

Executive Summary

Paras Biopharmaceuticals Finland Oy is a privately held Finnish biopharmaceutical company founded in 2012, specializing in the development of biosimilars. The company brings together a team of experienced protein scientists, bioprocess engineers, and technologists focused on efficient biologics development. Based in Oulu, Finland, Paras Biopharmaceuticals aims to address the growing global demand for affordable biologic therapies by leveraging its expertise in protein science and bioprocess optimization. While the company has not yet disclosed specific pipeline candidates or commercial products, its established team and strategic focus on biosimilars position it well within the competitive landscape. The biosimilar market continues to expand as patents for major biologics expire, offering opportunities for smaller, specialized firms like Paras Biopharmaceuticals to partner with larger pharmaceutical companies or bring cost-effective alternatives to market. Continued progress in its internal programs and potential collaborations will be key value drivers.

Upcoming Catalysts (preview)

• H2 2026Announcement of lead biosimilar candidate entering clinical trials70% success
• 2026Partnership or licensing deal with a major pharmaceutical company50% success
• 2027Regulatory filing for a biosimilar in a key market (e.g., EU or US)30% success